Zepbound denials in California external review
In the California DMHC record, independent physician reviewers decided 657 published external-review cases involving Zepboundand overturned the plan’s denial in 91.5%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
By condition
| Condition | Decisions | Overturned |
|---|---|---|
| Obesity | 591 | 92.4% |
| Obstructive Sleep Apnea | 71 | 91.5% |
| Hyperlipidemia | 20 | 95% |
| Pre-diabetes | 14 | 92.9% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 654 | 91.4% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 3 | 100% |
What the reviewers wrote
Where the denial was overturned
Findings: The physician reviewer found that the patient has requested authorization and coverage for Zepbound. Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Zepbound auto-injector pen. Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
Where the denial was upheld
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Zepbound. Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
The patient has requested authorization and coverage for Zepbound solution auto-injector. Obesity is a multi-causal chronic disease recognized across a patient’s lifespan resulting from long-term positive energy balance and the development of excess adiposity that, over time, leads to structural abnormalities, physiological derangements, and functional impairments. The disease of obesity increases the risk of developing other chronic diseases and is associated with premature mortality. As with other chronic diseases, obesity is distinguished by multiple phenotypes, clinical presentations, and treatment responses. The U.S.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Zepbound — and what reviewed cases show
Zepbound (tirzepatide) is FDA-approved for: chronic weight management; moderate-to-severe obstructive sleep apnea in adults with obesity. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
“Weight-loss drugs excluded” boilerplate
The most common Zepbound denial isn't about you at all — it's a category exclusion of anti-obesity medication. But Zepbound is also FDA-approved for obstructive sleep apnea in adults with obesity, an indication a “cosmetic” exclusion was never written to reach.
Sleep-apnea indication ignored
Plans processing Zepbound requests under their weight-loss criteria sometimes never evaluate the OSA indication the prescriber actually wrote. If you have documented sleep apnea, a denial that analyzed the wrong indication is procedurally defective.
Step therapy and “try Wegovy first”
Some formularies prefer one GLP-1 and demand failure of it before covering another. Prescriber documentation of tolerability problems, plateaued response, or clinical reasons for tirzepatide specifically is what exception processes exist for.
BMI and comorbidity documentation
As with other anti-obesity medication, approvals turn on chart-documented BMI and weight-related comorbidities. Thin documentation — not thin evidence — drives many first-round denials.
“Fail another drug first” requirements have a formal exit: the step-therapy exception. Prior GLP-1 intolerance, contraindications, or documented clinical rationale for tirzepatide are the standard grounds, and plans must decide exception requests quickly.
Evidence cited in overturned Zepbound decisions
- Lead with the strongest on-label indication you qualify for. Documented obstructive sleep apnea plus obesity is an FDA-approved use that sidesteps “weight-loss exclusion” reasoning entirely.
- Attach sleep-study results, comorbidity documentation, and BMI history so the reviewer sees a chronic-disease case, not a lifestyle request.
- If the plan preferred a different GLP-1, have your prescriber state specifically why tirzepatide — dual GIP/GLP-1 action, prior semaglutide outcome, tolerability — is the appropriate agent.
- Demand the criteria document the denial applied; a denial that applied weight-loss criteria to an OSA prescription reviewed the wrong question.
The published California record contains 657 external-review decisions involving Zepbound; 91.5% were overturned. This historical rate does not predict another case. For the full class-wide picture — cross-indication strategy, exclusion language, and the record for every GLP-1 drug — see the GLP-1 denial appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Zepbound, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY